The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Antibody therapies for AML and MDS
Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, outlines the use of monoclonal antibodies in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), in particular highlighting the use of sabatolimab and magrolimab. Sabatolimab is an antibody therapy targeting TIM-3. Magrolimab is a first-in-class investigational monoclonal antibody targeting CD47. Dr Brunner discusses the use of these therapies and comments on their efficacy in patients with high-risk mutations, as well as giving an overview of other antibody therapies and combinations which are under investigation. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Andrew M. Brunner, MD, has participated in consultancy work for Novartis, Acceleron, Agios, BMS/Celgene and Takeda.
